LT4393545T - Nauji piperidinilindolo darinių naudojimo būdai - Google Patents

Nauji piperidinilindolo darinių naudojimo būdai

Info

Publication number
LT4393545T
LT4393545T LTEP24170648.0T LT24170648T LT4393545T LT 4393545 T LT4393545 T LT 4393545T LT 24170648 T LT24170648 T LT 24170648T LT 4393545 T LT4393545 T LT 4393545T
Authority
LT
Lithuania
Prior art keywords
piperidinyl
indole derivatives
novel uses
novel
indole
Prior art date
Application number
LTEP24170648.0T
Other languages
English (en)
Inventor
Jörg EDER
Richard Alexander Harrison
Boerje Haraldsson
Anna Svenja Schubart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT4393545T publication Critical patent/LT4393545T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEP24170648.0T 2017-08-31 2018-08-30 Nauji piperidinilindolo darinių naudojimo būdai LT4393545T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188870 2017-08-31

Publications (1)

Publication Number Publication Date
LT4393545T true LT4393545T (lt) 2026-01-12

Family

ID=59745840

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP24170648.0T LT4393545T (lt) 2017-08-31 2018-08-30 Nauji piperidinilindolo darinių naudojimo būdai
LTEPPCT/IB2018/056618T LT3675854T (lt) 2017-08-31 2018-08-30 Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2018/056618T LT3675854T (lt) 2017-08-31 2018-08-30 Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti

Country Status (22)

Country Link
US (3) US11723901B2 (lt)
EP (3) EP4393545B1 (lt)
JP (3) JP6754919B1 (lt)
KR (3) KR102682887B1 (lt)
CN (5) CN117398384A (lt)
AU (1) AU2018326768B2 (lt)
BR (1) BR112020003737A2 (lt)
CA (1) CA3073346A1 (lt)
CL (1) CL2020000483A1 (lt)
DK (2) DK3675854T3 (lt)
ES (2) ES3022885T3 (lt)
FI (2) FI3675854T3 (lt)
HR (2) HRP20250386T1 (lt)
HU (1) HUE071118T2 (lt)
IL (1) IL272888B2 (lt)
LT (2) LT4393545T (lt)
MX (3) MX2020002185A (lt)
PL (2) PL4393545T3 (lt)
PT (2) PT4393545T (lt)
RS (2) RS66635B1 (lt)
SI (2) SI4393545T1 (lt)
WO (1) WO2019043609A1 (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
WO2021125313A1 (ja) * 2019-12-19 2021-06-24 大鵬薬品工業株式会社 縮合ピリミジン化合物を有効成分とする治療剤
KR20250048392A (ko) 2020-05-18 2025-04-08 노파르티스 아게 Lnp023의 결정질 형태
US20230286947A1 (en) * 2020-08-07 2023-09-14 Shanghai Meiyue Biotech Development Co. Ltd Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof
US20230331710A1 (en) * 2020-08-07 2023-10-19 Shanghai Meiyue Biotech Development Co. Ltd Heterocyclic compound, preparation method and use thereof
CN119798256A (zh) * 2020-12-30 2025-04-11 江苏恒瑞医药股份有限公司 含氮桥杂环化合物、其制备方法及其在医药上的应用
JP7641388B2 (ja) * 2020-12-30 2025-03-06 エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド 一連のピペリジン置換安息香酸系化合物及びその使用
JP2024517234A (ja) * 2021-05-07 2024-04-19 ノバルティス アーゲー 非典型溶血性尿毒症症候群の処置のためのイプタコパン
CA3229360A1 (en) * 2021-08-18 2023-02-23 Chen Zhang Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
EP4423076A4 (en) * 2021-10-27 2026-01-07 Hansoh Bio Llc PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES
CR20240300A (es) * 2022-01-24 2024-08-23 Novartis Ag Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.
EP4471021A4 (en) * 2022-01-26 2025-04-30 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
CN119343347A (zh) * 2022-06-10 2025-01-21 正大天晴药业集团股份有限公司 双环取代的芳香羧酸酯类化合物
WO2023246677A1 (zh) * 2022-06-20 2023-12-28 深圳信立泰药业股份有限公司 一种吲哚-苯基哌啶化合物及其制备方法与应用
US20250382287A1 (en) 2022-06-30 2025-12-18 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same
CN117327070A (zh) * 2022-06-30 2024-01-02 江苏恒瑞医药股份有限公司 一种含氮桥杂环衍生物的晶型及其制备方法
JP2025530222A (ja) * 2022-09-10 2025-09-11 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ２－置換ピペリジン誘導体、その製造方法及び医薬的用途
EP4617266A1 (en) 2022-11-11 2025-09-17 Shanghai Yisheng Biopharmaceutical company Limited Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
WO2024141011A1 (zh) * 2022-12-31 2024-07-04 深圳晶泰科技有限公司 补体因子b抑制剂及其药物组合物和应用
TWI896250B (zh) * 2023-07-26 2025-09-01 大陸商上海美悦生物科技發展有限公司 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途
WO2026086939A1 (zh) * 2024-10-25 2026-04-30 上海美悦生物科技发展有限公司 杂环化合物在制备预防或治疗IgA肾病的药物中的用途
WO2026093943A1 (en) 2024-10-31 2026-05-07 Novartis Ag Chemical process for preparing phenylpiperidinyl indole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
ES2712190T3 (es) 2012-06-28 2019-05-09 Novartis Ag Moduladores de la vía del complemento y sus usos
CN105229003B (zh) * 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
JO3425B1 (ar) * 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
SG11201805695SA (en) * 2016-01-05 2018-07-30 Univ Leicester Methods for inhibiting fibrosis in a subject in need thereof
BR112020003737A2 (pt) 2017-08-31 2020-09-01 Novartis Ag usos de derivados de piperidinil-indol
KR20250048392A (ko) 2020-05-18 2025-04-08 노파르티스 아게 Lnp023의 결정질 형태
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors

Also Published As

Publication number Publication date
US20220152011A1 (en) 2022-05-19
EP4647121A2 (en) 2025-11-12
FI3675854T3 (fi) 2025-04-07
PT3675854T (pt) 2025-04-04
EP3675854B1 (en) 2025-01-22
WO2019043609A1 (en) 2019-03-07
HRP20250386T1 (hr) 2025-05-23
JP6754919B1 (ja) 2020-09-16
JP2020529466A (ja) 2020-10-08
LT3675854T (lt) 2025-04-25
RU2020111788A3 (lt) 2021-12-28
EP4393545A3 (en) 2024-09-25
US12285422B2 (en) 2025-04-29
KR102682887B1 (ko) 2024-07-08
RS67530B1 (sr) 2026-01-30
KR20200047540A (ko) 2020-05-07
CN111032042A (zh) 2020-04-17
EP4647121A3 (en) 2026-02-18
JP6929425B2 (ja) 2021-09-01
ES3022885T3 (en) 2025-05-29
EP4393545A2 (en) 2024-07-03
RS66635B1 (sr) 2025-04-30
DK3675854T3 (da) 2025-04-07
DK4393545T3 (da) 2026-01-12
AU2018326768A1 (en) 2020-02-06
IL272888A (en) 2020-04-30
SI4393545T1 (sl) 2026-02-27
KR20240111007A (ko) 2024-07-16
US20200338059A1 (en) 2020-10-29
MX2023010750A (es) 2023-09-20
ES3058507T3 (en) 2026-03-11
MX2023010751A (es) 2023-09-20
BR112020003737A2 (pt) 2020-09-01
PL4393545T3 (pl) 2026-03-16
IL272888B1 (en) 2023-09-01
KR102497487B1 (ko) 2023-02-08
EP3675854A1 (en) 2020-07-08
CN117338782A (zh) 2024-01-05
CN117338781A (zh) 2024-01-05
FI4393545T3 (fi) 2026-01-14
CN117398384A (zh) 2024-01-16
CA3073346A1 (en) 2019-03-07
US20250195493A1 (en) 2025-06-19
PT4393545T (pt) 2025-12-23
CL2020000483A1 (es) 2020-09-04
HRP20251596T1 (hr) 2026-01-30
SI3675854T1 (sl) 2025-05-30
RU2020111788A (ru) 2021-09-30
IL272888B2 (en) 2024-01-01
AU2018326768B2 (en) 2021-07-29
EP4393545B1 (en) 2025-10-08
CN117338783A (zh) 2024-01-05
PL3675854T3 (pl) 2025-05-19
HUE071118T2 (hu) 2025-08-28
KR20230024432A (ko) 2023-02-20
JP2020193222A (ja) 2020-12-03
US11723901B2 (en) 2023-08-15
JP7297016B2 (ja) 2023-06-23
MX2020002185A (es) 2020-07-14
JP2021181471A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
IL272888B1 (en) Uses of piperidinyl-indole derivatives
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
IL271607A (en) New azaquinoline histories
SG11201706729SA (en) Derivatives of sobetirome
PL3645518T3 (pl) Synteza omekamtywu mekarbilu
SMT202100551T1 (it) Derivati di sobetirome
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
IL276592A (en) History of Subtirum
IL274627A (en) Solid forms of valbenazine
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL272697A (en) A polymorphic form of TG02
IL265628A (en) Solid state forms of valbenazine
IL272857A (en) Cofanalisib formulations
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL293192A (en) Methods for the preparation of indolinobenzodiazepine derivatives
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
EP3468578A4 (en) USES OF IL-41
IL270703B1 (en) History of Reziquimod
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
IL263363A (en) Polymorph of nintedanib
IL254666A0 (en) Crystalline forms of Aldecalcitol
GB201721386D0 (en) Chrondogy of time-wave
AU2017904670A0 (en) Improvement of clothes-hangers
HK40006442A (en) Derivatives of sobetirome
HK40007680A (en) N-carboxyanhydride-based-scale synthesis of elamipretide